PDCD1 and neoplasm: For instance, blockers of programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) indicate that there are broad and diverse opportunities for enhancing anti-tumor immunity by modulating the immune responses (Pardoll, 2012).